Pregnant women with inflammatory arthritis may have an increased risk for preterm delivery. New research examined the risk of preterm delivery and other pregnancy complications in women with RA and JIA vs. healthy controls…
CMS Proposes Major Payment Increases for E/M Services
CMS estimates that under their proposal, released July 29, rheumatologists would see on average a 15% payment increase, beginning in 2021.
Cigna to Eliminate Consultation Codes
Cigna recently announced that they will discontinue payment for consultation codes later this year. As of Oct. 19, 2019, the payer will implement a new policy on Evaluation and Management (R30) that will deny claims billed with CPT codes for consultation services as not valid. Impacted CPT codes are 99241, 99242, 99243, 99244, 99245, 99251,…
Healthcare Professionals Can Tap the ARP for Assistance
The ARP has a lot to offer members, including training and professional development, patient resources and volunteer match opportunities.
RheumPAC Advocates for Department of Defense Arthritis Research Funding
The ACR’s nonpartisan political action committee is continuing to advocate for increased defense department funding for rheumatology research. Learn about RheumPAC’s efforts and how you can help.
White House Preparing Order that Would Cut Drug Prices for Medicare
(Reuters)—U.S. President Donald Trump is considering a sweeping executive order that would cut prices on virtually all branded prescription drugs sold to Medicare and other government programs, according to two industry sources who had discussions with the White House. The order under discussion would be much broader than the Administration’s previously disclosed proposal to lower…
Drug Makers Met with Trump to Argue against Senate Pricing Bill
(Reuters)—The main pharmaceutical industry lobbying group said on Thursday it and some drugmakers met with President Donald Trump to voice opposition to a bipartisan U.S. Senate bill that aims to lower prescription drug prices. The White House, which has said it backs the legislation, has promised to bring down drug prices for U.S. consumers, an…
Samsung Bioepis Humira Biosimilar Wins FDA Approval
(Reuters)—The U.S. Food and Drug Administration approved Samsung Bioepis Co. Ltd.’s biosimilar to AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, the health agency said on Tuesday. The drug, Hadlima, was developed by South Korea’s Samsung Bioepis and comes with a boxed warning, the FDA’s harshest. The agency flagged increased risk of serious infections, including tuberculosis…
RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
Peripheral Arthritis & Recent Onset Axial SpA: 5-Year Results from the DESIR Cohort
An analysis of follow-up data from the DESIR cohort showed patients with recent onset axial spondyloarthritis who experienced peripheral arthritis had worse symptoms and quality of life long term. In the study, peripheral arthritis was also associated with negative HLAB27, non-smoking and the presence of other peripheral disease manifestations…
- « Previous Page
- 1
- …
- 249
- 250
- 251
- 252
- 253
- …
- 814
- Next Page »